BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Papatheodoridi M, Papatheodoridis G. Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B. Cells. 2020;9. [PMID: 32093411 DOI: 10.3390/cells9020493] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Papatheodoridi M, Papatheodoridis G. New concepts in the finite oral antiviral therapy in HBeAg-negative chronic hepatitis B. J Hepatol 2021:S0168-8278(21)00440-2. [PMID: 34171438 DOI: 10.1016/j.jhep.2021.06.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Panevkina S, Ibragimov E, Abdurakhmanov D. High Rate of Virologic Response After Discontinuation of Nucleos(T)Ide Analogues in Caucasian Chronic Hepatitis B Patients. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00101-4. [PMID: 33548510 DOI: 10.1016/j.cgh.2021.01.050] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Xue Y, Zhang M, Li T, Liu F, Zhang LX, Fan XP, Yang BH, Wang L. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss. World J Gastroenterol 2021; 27(14): 1497-1506 [PMID: 33911470 DOI: 10.3748/wjg.v27.i14.1497] [Reference Citation Analysis]
4 Liao G, Liu Z, Xia M, Chen H, Wu H, Li B, Yu T, Cai S, Zhang X, Peng J. Soluble Programmed Cell Death-1 is a Novel Predictor of HBsAg Loss in Chronic Hepatitis B Patients When Long-Term Nucleos(t)ide Analog Treatment is Discontinued. IDR 2022;Volume 15:2347-57. [DOI: 10.2147/idr.s360202] [Reference Citation Analysis]
5 Jindal A. Severity of Hepatitis B Relapse After Cessation of Nucleos(t)ide Analog: Need a Closer Look! Clin Gastroenterol Hepatol 2021:S1542-3565(21)00968-X. [PMID: 34508869 DOI: 10.1016/j.cgh.2021.09.004] [Reference Citation Analysis]
6 Zuccaro V, Asperges E, Colaneri M, Marvulli LN, Bruno R. HBV and HDV: New Treatments on the Horizon. J Clin Med 2021;10:4054. [PMID: 34575165 DOI: 10.3390/jcm10184054] [Reference Citation Analysis]
7 Liaw YF. Hepatitis B Flare After Cessation of Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B: To Retreat or Not to Retreat. Hepatology 2021;73:843-52. [PMID: 32810321 DOI: 10.1002/hep.31525] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
8 Chien RN, Liaw YF. Current Trend in Antiviral Therapy for Chronic Hepatitis B. Viruses 2022;14:434. [PMID: 35216027 DOI: 10.3390/v14020434] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Berg T, Lampertico P. The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analogue therapy. J Hepatol 2021;75:474-80. [PMID: 33957187 DOI: 10.1016/j.jhep.2021.04.040] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]